Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Ian Taylor sold 9,020 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Arvinas Stock Up 2.5 %
Shares of ARVN traded up $0.44 during trading hours on Friday, hitting $17.70. 932,873 shares of the company were exchanged, compared to its average volume of 1,027,486. Arvinas, Inc. has a fifty-two week low of $16.07 and a fifty-two week high of $51.51. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -6.39 and a beta of 1.88. The firm's fifty day moving average is $18.37 and its 200 day moving average is $22.72.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the company posted ($2.53) EPS. Analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on ARVN shares. Stephens began coverage on Arvinas in a report on Monday, November 18th. They set an "overweight" rating and a $55.00 target price on the stock. Wedbush reiterated an "outperform" rating and issued a $57.00 price objective on shares of Arvinas in a report on Tuesday, February 11th. Guggenheim reissued a "buy" rating and issued a $57.00 price objective on shares of Arvinas in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. Finally, Barclays lowered their price target on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Arvinas presently has a consensus rating of "Buy" and an average price target of $60.00.
Read Our Latest Analysis on ARVN
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in ARVN. Assenagon Asset Management S.A. acquired a new stake in shares of Arvinas in the 3rd quarter valued at $3,442,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after buying an additional 440 shares during the last quarter. abrdn plc boosted its stake in Arvinas by 27.8% in the third quarter. abrdn plc now owns 78,585 shares of the company's stock valued at $1,936,000 after buying an additional 17,093 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Arvinas by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,203 shares of the company's stock valued at $325,000 after acquiring an additional 5,163 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Arvinas during the third quarter worth about $350,000. 95.19% of the stock is owned by institutional investors.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Read More
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
